Glamour isn’t just for the rich and famous. As the ‘Ball Without Billionaires’ showed, the blue collar can bedazzle.

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, ...

As companies race to build more powerful AI, they’re running into energy constraints. Data centers increasingly require enormous amounts of energy, and existing infrastructure is already strained.

JS runtimes are GenServers. They live in supervision trees, send and receive messages, and call into Erlang/OTP libraries — all without leaving the BEAM.

From Bad Bunny's Super Bowl LX halftime show look to the Met Gala dress code, these are the style moments and trends that have made the most noise in 2026. How to Wear and Style Timberland Boots and ...

This article is part of Kotaku Deals, produced separately from the editorial team. We may earn a commission when you buy through links on the site. The Sonos Beam Gen 2 Soundbar with Dolby Atmos is ...

The Luxor Sky Beam pierces the night sky above the Luxor Hotel and Casino in Las Vegas. It attracts thousands of visitors each year to marvel at the spectacle, but it also has a profound effect on the ...

The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to ...

Almost exactly a year ago to the day, Pfizer withdrew the hemophilia B gene therapy Beqvez from the market and ended all work on it. Now, the pharma wants back in the genetics game, inking a global ...

is a deputy editor and Verge co-founder with a passion for human-centric cities, e-bikes, and life as a digital nomad. He’s been a tech journalist for 20 years. Light-based internet provider Taara, ...

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a ...